Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mammalian orthoreovirus (reovirus) is a double-stranded RNA (dsRNA) virus used as an oncolytic agent to selectively infect and kill cancer cells. It preferentially replicates in transformed cells with activated Ras signaling, leading to cell death via apoptosis, necroptosis, and autophagy. Reovirus also modulates the tumor microenvironment by stimulating immune responses and reducing immunosuppression. It is under investigation as a form of cancer virotherapy, often in combination with chemotherapy, radiation, or immunotherapies.
Selective replication in cancer cells with activated Ras signaling pathways, leading to cell lysis and immunomodulation. Induces apoptosis, necroptosis, and autophagy in tumor cells. Stimulates innate and adaptive immunity and reduces MDSC suppression.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mammalian Orthoreovirus (Reovirus).